Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The serine biosynthesis pathway is a central metabolic route that converts glycolytic intermediate 3-phosphoglycerate to L-serine via three primary enzymatic steps involving phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase (PSAT), and phosphoserine phosphatase (PSPH)[1][2][3][5]. L-serine is a nonessential but proteinogenic amino acid fundamental for protein, nucleotide, and phospholipid biosynthesis, as well as for providing one-carbon units required for methylation reactions[1][2][5]. The activity of this pathway supports cell proliferation and growth, making it critically important in rapidly dividing cells such as cancer cells[3]. Pathological alterations in this pathway are associated with congenital serine deficiency syndromes and play roles in tumor metabolic reprogramming[2][3].
Enzyme inhibition (notably of PHGDH, the first committed enzyme in the pathway)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine biosynthesis pathway.